Cardiac Acetylation in Metabolic Diseases - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Biomedicines Year : 2022

Cardiac Acetylation in Metabolic Diseases


Lysine acetylation is a highly conserved mechanism that affects several biological processes such as cell growth, metabolism, enzymatic activity, subcellular localization of proteins, gene transcription or chromatin structure. This post-translational modification, mainly regulated by lysine acetyltransferase (KAT) and lysine deacetylase (KDAC) enzymes, can occur on histone or non-histone proteins. Several studies have demonstrated that dysregulated acetylation is involved in cardiac dysfunction, associated with metabolic disorder or heart failure. Since the prevalence of obesity, type 2 diabetes or heart failure rises and represents a major cause of cardiovascular morbidity and mortality worldwide, cardiac acetylation may constitute a crucial pathway that could contribute to disease development. In this review, we summarize the mechanisms involved in the regulation of cardiac acetylation and its roles in physiological conditions. In addition, we highlight the effects of cardiac acetylation in physiopathology, with a focus on obesity, type 2 diabetes and heart failure. This review sheds light on the major role of acetylation in cardiovascular diseases and emphasizes KATs and KDACs as potential therapeutic targets for heart failure.
Fichier principal
Vignette du fichier
biomedicines-10-01834-v2.pdf (1.01 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-03833000 , version 1 (28-10-2022)



Emilie Dubois-Deruy, Yara El Masri, Annie Turkieh, Philippe Amouyel, Florence Pinet, et al.. Cardiac Acetylation in Metabolic Diseases. Biomedicines, 2022, 10 (8), pp.1834. ⟨10.3390/biomedicines10081834⟩. ⟨inserm-03833000⟩
7 View
10 Download



Gmail Facebook Twitter LinkedIn More